Akero Therapeutics to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
A live webcast of the presentation and Q&A will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients. The Company's lead product candidate, AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial.
View original content to download multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-present-at-hc-wainwrights-4th-annual-nash-virtual-investor-conference-301139211.html
SOURCE
Investors, Christina Tartaglia, Stern Investor Relations, Inc., 212.362.1200, christina@sternir.com; Media, Carolyn Hawley, Canale Communications, 619.849.5382, carolyn@canalecomm.com